Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 6/20 | 0.73 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.73 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.73 |
| ▸ | HTR3A | P46098 | 4/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL232167 | 0.92 | CHRNA7 (0.63) | CHRNA7CHRNB4CHRNA3HTR3AKCNH2 | |
| SCHEMBL232160 | 0.87 | CHRNA7 (0.68) | CHRNA7CHRNB4CHRNA3HTR3AKCNH2 | |
| SCHEMBL19488944 | 0.87 | CHRNA7 (0.82) | CHRNA7CHRNB4CHRNA3HTR3AKCNH2 | |
| SCHEMBL230959 | 0.86 | CHRNA7 (0.79) | CHRNA7CHRNB4CHRNA3HTR3AKCNH2 | |
| SCHEMBL233116 | 0.85 | CHRNA7 (1.00) | CHRNA7CHRNB4CHRNA3HTR3AKCNH2 | |
| SCHEMBL18016314 | 0.85 | CHRNA7 (1.00) | CHRNA7CHRNB4CHRNA3HTR3AKCNH2 | |
| SCHEMBL2637916 | 0.81 | CHRNA7 (0.67) | CHRNA7CHRNB4CHRNA3HTR3A | |
| Fumaric Acid SCHEMBL232394 | 0.79 | CHRNA7 (0.68) | CHRNA7CHRNB4CHRNA3HTR3AKCNH2 | |
| SCHEMBL232153 | 0.79 | CHRNA7 (0.65) | CHRNA7CHRNB4CHRNA3HTR3AKCNH2 | |
| Fumaric Acid SCHEMBL232246 | 0.78 | CHRNA7 (0.85) | CHRNA7CHRNB4CHRNA3HTR3AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8778928-B2 | Indolyl-oxadiazolyl-diazabicyclononane derivatives and their medical and diagnostical use | DANPET AB (SE) | 2014-07-15 | — | — | US | claimed |
| US-20120003153-A1 | NOVEL INDOLYL-OXADIAZOLYL-DIAZABICYCLONONANE DERIVATIVES AND THEIR MEDICAL AND DIAGNOSTICAL USE | NEUROSEARCH A/S (DK) | 2012-01-05 | — | — | US | claimed |
| EP-2389181-A1 | NOVEL INDOLYL-OXADIAZOLYL-DIAZABICYCLONONANE DERIVATIVES AND THEIR MEDICAL AND DIAGNOSTICAL USE | NeuroSearch A/S (DK) | 2011-11-30 | — | — | EP | claimed |
| US-20110253589-A1 | IMPACT-ABSORBING PACKAGE | Innovative Enterprises, Inc (US) | 2011-10-20 | — | — | US | claimed |
| WO-2010084185-A1 | NOVEL INDOLYL-OXADIAZOLYL-DIAZABICYCLONONANE DERIVATIVES AND THEIR MEDICAL AND DIAGNOSTICAL USE | NEUROSEARCH A/S (DK) | 2010-07-29 | — | — | WO | claimed |
| US-8778928-B2 | Indolyl-oxadiazolyl-diazabicyclononane derivatives and their medical and diagnostical use | DANPET AB (SE) | 2014-07-15 | — | — | US | disclosed |
| US-20120003153-A1 | NOVEL INDOLYL-OXADIAZOLYL-DIAZABICYCLONONANE DERIVATIVES AND THEIR MEDICAL AND DIAGNOSTICAL USE | NEUROSEARCH A/S (DK) | 2012-01-05 | — | — | US | disclosed |
| EP-2389181-A1 | NOVEL INDOLYL-OXADIAZOLYL-DIAZABICYCLONONANE DERIVATIVES AND THEIR MEDICAL AND DIAGNOSTICAL USE | NeuroSearch A/S (DK) | 2011-11-30 | — | — | EP | disclosed |
| US-20110253589-A1 | IMPACT-ABSORBING PACKAGE | Innovative Enterprises, Inc (US) | 2011-10-20 | — | — | US | disclosed |
| WO-2010084185-A1 | NOVEL INDOLYL-OXADIAZOLYL-DIAZABICYCLONONANE DERIVATIVES AND THEIR MEDICAL AND DIAGNOSTICAL USE | NEUROSEARCH A/S (DK) | 2010-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120003153-A1 | NOVEL INDOLYL-OXADIAZOLYL-DIAZABICYCLONONANE DERIVATIVES AND THEIR MEDICAL AND DIAGNOSTICAL USE | CHRNA6, CHRNA10, CHRNA3 | CHRNA7 4/4885CHRNB4 14/4885CHRNA3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.